EVOTEC SE INH O.N./ DE0005664809 /
11/8/2024 9:58:41 PM | Chg. -0.100 | Volume | Bid9:58:41 PM | Ask9:58:41 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
7.700EUR | -1.28% | 718,863 Turnover: 5.67 mill. |
7.620Bid Size: 2,000 | 7.700Ask Size: 1,100 | 1.35 bill.EUR | - | - |
GlobeNewswire
12/11/2023
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune c...
GlobeNewswire
11/7/2023
Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
GlobeNewswire
2/15/2018
EVOTEC AG AND MARS INNOVATION ANNOUNCE FIRST FUNDED PROJECT UNDER LAB150 BRIDGE
GlobeNewswire
1/8/2018
APEIRON and Evotec Achieve First Milestone in Immuno-oncology Alliance with Sanofi
GlobeNewswire
11/29/2011
Directors' dealings:Evotec AG:Director's Dealings announcement according to §15a WpHG (the German Se...
GlobeNewswire
10/27/2011
Evotec Achieves Two Milestones in Fragment-based Drug Discovery Alliance with Shionogi
GlobeNewswire
9/9/2011
Directors' dealings:Evotec AG:Director's Dealings announcement according to §15a WpHG (the German Se...
GlobeNewswire
9/5/2011
Evotec and Roche agree to develop compound that could slow the progression of Alzheimer's disease
GlobeNewswire
9/5/2011
Evotec AG:Ad hoc:Evotec and Roche agree to develop compound that could slow the progression of Alzhe...
GlobeNewswire
8/18/2011
Evotec Receives Pre-clinical Milestone Payment as Part of its Discovery Alliance with Boehringer In...
GlobeNewswire
8/11/2011
Evotec reports 34% revenue and profitable earnings growth; revenue guidance raised
GlobeNewswire
8/11/2011
Evotec partners P2X7 antagonist programme, EVT 401, to a top tier global animal health company